ICI 89406

Discontinued Product

0832 has been discontinued.

View all Non-selective Adrenergic β Receptors products.
说明: β antagonist
化学名: N-[2-[3-(2-Cyanophenoxy)-2-hydroxypropylamino]ethyl]-N'-phenylurea
纯度: ≥99% (HPLC)
说明书
引用文献 (2)
评论
文献 (1)

生物活性 for ICI 89406

β-adrenergic antagonist and low efficacy partial agonist; does not affect resting cardiac parameters.

许可信息

Sold with the permission of AstraZeneca UK Ltd.

技术数据 for ICI 89406

分子量 354.41
公式 C19H22N4O3
储存 Store at RT
纯度 ≥99% (HPLC)
CAS Number 53671-71-9
PubChem ID 123686
InChI Key HTLWRKRZKFAAAH-UHFFFAOYSA-N
Smiles OC(CNCCNC(=O)NC1=CC=CC=C1)COC1=C(C=CC=C1)C#N

上方提供的技术数据仅供参考。批次相关数据请参见分析证书。

Tocris products are intended for laboratory research use only, unless stated otherwise.

参考文献 for ICI 89406

参考文献是支持产品生物活性的出版物。

Mai (1990) β-Adrenergic Receptors. Comprehensive Medicinal Chemistry. Ed. Hansch. 3 187

关键词: ICI 89406, ICI 89406 supplier, β-adrenoceptor, beta-adrenoceptor, b-adrenoceptor, β-adrenergic, beta-adrenergic, b-adrenergic, antagonists, Receptors, Non-Selective, ICI89406, AstraZeneca, Non-selective, Adrenergic, Beta, 0832, Tocris Bioscience

2 篇 ICI 89406 的引用文献

引用文献是使用了 Tocris 产品的出版物。 ICI 89406 的部分引用包括:

Mistry et al (2013) Synthesis and in vitro and in vivo characterization of highly β1-selective β-adrenoceptor partial agonists. J Med Chem 56 3852 PMID: 23614528

Kaya et al (2009) Coupling of β2-adrenoceptors to XLαs and Gαs: a new insight into ligand-induced G protein activation. J Pharmacol Exp Ther 329 350 PMID: 19144685


ICI 89406 的评论

目前没有该产品的评论。 Be the first to review ICI 89406 and earn rewards!

Have you used ICI 89406?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

该领域的文献

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。


Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.